Trial of Psilocybin versus Escitalopram for Depression.

@article{CarhartHarris2021TrialOP,
  title={Trial of Psilocybin versus Escitalopram for Depression.},
  author={Robin Lester Carhart-Harris and Bruna Giribaldi and Rosalind Watts and Michelle Baker-Jones and Ashleigh Murphy-Beiner and Robert Murphy and Jonny Martell and Allan Blemings and David Erritzoe and David J. Nutt},
  journal={The New England journal of medicine},
  year={2021},
  volume={384 15},
  pages={
          1402-1411
        }
}
BACKGROUND Psilocybin may have antidepressant properties, but direct comparisons between psilocybin and established treatments for depression are lacking. METHODS In a phase 2, double-blind, randomized, controlled trial involving patients with long-standing, moderate-to-severe major depressive disorder, we compared psilocybin with escitalopram, a selective serotonin-reuptake inhibitor, over a 6-week period. Patients were assigned in a 1:1 ratio to receive two separate doses of 25 mg of… 

Figures and Tables from this paper

Psilocybin-assisted therapy for the treatment of resistant major depressive disorder (PsiDeR): protocol for a randomised, placebo-controlled feasibility trial
TLDR
Psilocybin-assisted therapy may be a new treatment for major depressive disorder (MDD), with encouraging data from pilot trials, and this trial aimed to test the feasibility of a parallel-group, randomised, placebo-controlled design.
Rediscovering Psilocybin as an Antidepressive Treatment Strategy
TLDR
An overview of the current state of research on the potential mechanisms of psilocybin, its antidepressant potential, and the associated risks and adverse effects is provided to provide an update on a controversial topic discussed in psychopharmacology.
The Potential Role of Serotonergic Hallucinogens in Depression Treatment
TLDR
The reviewed studies suggest that psychedelics have great potential in depression therapy and, after addressing and overcoming the current study limitations, may be used as a novel method of treating depression in the future.
Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression
TLDR
The aim of this review is to synthesize the current understanding of the receptor pharmacology and neuronal mechanisms underlying the psychedelic and putative antidepressant properties of psilocybin.
Study Protocol for “Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study”
TLDR
The results of this pilot study will not only shed light on the acceptability, brain mechanisms, and impression of the potential efficacy of psilocybin as an adjunct treatment for AN but will be essential in shaping a subsequent Randomised Control Trial (RCT) that would test this treatment against a suitable control condition.
Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder
TLDR
Findings suggest a nuanced relationship between cognitive and neural flexibility, whereas some enduring increases in neural dynamics may allow for shifting out of a maladaptively rigid state, larger persisting increases in Neural dynamics may be of less benefit to psilocybin therapy.
Is MDD the right target for early-stage psychedelic-assisted therapy trials?
The recently published Imperial College study of a Phase II, double-blind, randomized, controlled trial comparing psilocybin-assisted therapy to a six-week titration of escitalopram for Major
Psilocybin and MDMA for the treatment of trauma-related psychopathology
TLDR
The therapeutic rationale of both psilocybin- and 3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treating both trauma-related MDD and PTSD is reviewed.
Evaluating pimavanserin as a treatment for psychiatric disorders: A pharmacological property in search of an indication
TLDR
Pimavanserin augmentation of antipsychotics did benefit negative symptoms but failed to reduce the total PANSS score significantly in two large, well-controlled double-blind studies.
Psilocybin modulation of dynamic functional connectivity is associated with plasma psilocin and subjective effects
TLDR
The findings suggest that the acute perceptual psychedelic effects induced by psilocybin may stem from drug-level associated decreases in the occurrence and duration of lateral and medial frontoparietal connectivity motifs in exchange for increases in a uniform connectivity structure.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 28 REFERENCES
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.
TLDR
Preliminary support for the safety and efficacy of psilocybin for treatment-resistant depression is provided and motivates further trials, with more rigorous designs, to better examine the therapeutic potential of this approach.
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
TLDR
Although limited conclusions can be drawn about treatment efficacy from open-label trials, tolerability was good, effect sizes large and symptom improvements appeared rapidly after just two psilocybin treatment sessions and remained significant 6 months post-treatment in a treatment-resistant cohort.
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
TLDR
High-dose psilocybin produced large decreases in clinician- and self-rated measures of depressed mood and anxiety, along with increases in quality of life, life meaning, and optimism, and decreases in death anxiety.
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial
TLDR
Psilocybin was associated with enduring anxiolytic and anti-depressant effects in patients with cancer-related psychological distress, sustained benefits in existential distress and quality of life, as well as improved attitudes towards death.
Escitalopram versus other antidepressive agents for depression.
TLDR
Some statistically significant differences favouring escITALopram over other antidepressive agents for the acute phase treatment of major depression were found, in terms of efficacy (citalopram and fluoxetine) and acceptability (duloxettine).
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression
TLDR
The view that the quality of the acute psychedelic experience is a key mediator of long-term changes in mental health is bolstered, as data from a clinical trial assessing psilocybin for treatment-resistant depression confirmed this.
Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.
TLDR
This study established the feasibility and safety of administering moderate doses of psilocybin to patients with advanced-stage cancer and anxiety and revealed a positive trend toward improved mood and anxiety.
Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers.
TLDR
It is suggested that headache is an adverse event to be expected with the nonmedical use of psilocybin-containing mushrooms as well as the administration of p silocybin in human research.
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
TLDR
The response and remission rates in this highly generalizable sample with substantial axis I and axis III comorbidity closely resemble those seen in 8-week efficacy trials.
Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels
TLDR
It is reported for the first time that intake of psilocybin leads to significant 5-HT2AR occupancy in the human brain, and that both psilocin plasma levels and5-HT 2AR occupancy are closely associated with subjective intensity ratings, strongly supporting that stimulation of 5- HT2AR is a key determinant for the psychedelic experience.
...
1
2
3
...